Cyto-Facto Inc. provides services for manufacturing, development, and quality control testing of gene and cell preparations

We are pleased to announce that our company, Cyto-Facto, has been included in the "Regenerative Medicine CDMO List" published by the Ministry of Economy, Trade and Industry (METI) on April 1.
 

"Regenerative Medicine CDMO List"
https://firm.or.jp/cdmo/
 

This CDMO list was created through collaboration between METI and the Forum for Innovative Regenerative Medicine (FIRM) to address challenges in manufacturing within the fields of regenerative medicine, cell therapy, and gene therapy. By facilitating the matching of academia and biotech ventures—key players in drug discovery—with CDMOs, the initiative aims to accumulate expertise in manufacturing process development within Japan, ultimately strengthening the country’s drug discovery capabilities.
 

For inquiries regarding contract manufacturing, quality testing, or other services, please contact us via our [inquiry page].